ProKidney (PROK)

• Market cap: $302M
• 1 day: -2.29%
• 5 days: 6.5%
• 1 month: 10.36%
• 3 months: -0.47%
• 6 months: -35.26%
• Year to date: -4.48%
• 1 year: 190.63%
• 5 years: -78.93%
• 10 years: -78.93%
• Sector: Healthcare
• Industry: Biotechnology

About: ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Employees: 231